inhibitors New-Onset

New-Onset IBD and IL-17 Inhibitors: What Is the Risk?

Patients with inflammatory/autoimmune diseases who initiated treatment with interleukin (IL)-17 inhibitors did not have a higher risk for the development of inflammatory bowel disease (IBD), but only after taking into account the severity of their underlying disease, French investigators reported. Although the risk of IBD was significantly higher among initiators of IL-17 inhibition compared with…

anxiety New-Onset

New-Onset Anxiety, Depression an Ongoing Risk for ICD Patients

Testing for anxiety or depression should be offered periodically — perhaps for months to years — to patients with implantable cardioverter defibrillators (ICD), not just in the early period after implantation, suggests a prospective cohort study. Results showed a 2% to 4% rate of new-onset anxiety and depression at each of four scheduled follow-up assessments…